OA11340A - Method for the synthesis of quinoline derivatives. - Google Patents

Method for the synthesis of quinoline derivatives. Download PDF

Info

Publication number: OA11340A
Authority: OA; OAPI
Prior art keywords: formula; alkyl; reaction mixture; compound; hydroxy
Prior art date: 1997-09-17

Application number

OA1200000078A

Other languages

English (en)

Inventor

Joseph Sisko

Mark Mellinger

Conrad Kowalski

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-17

Filing date

2000-03-16

Publication date

2003-12-09

2000-03-16 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2003-12-09 Publication of OA11340A publication Critical patent/OA11340A/en

Links

238000000034 method Methods 0.000 title claims abstract description 52
230000015572 biosynthetic process Effects 0.000 title description 16
238000003786 synthesis reaction Methods 0.000 title description 14
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title description 2
229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 129
239000011541 reaction mixture Substances 0.000 claims description 100
125000000217 alkyl group Chemical group 0.000 claims description 96
229910052739 hydrogen Inorganic materials 0.000 claims description 47
239000001257 hydrogen Substances 0.000 claims description 47
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
-1 cyano, carboxy Chemical group 0.000 claims description 45
229910052736 halogen Inorganic materials 0.000 claims description 35
150000002367 halogens Chemical class 0.000 claims description 35
239000002904 solvent Substances 0.000 claims description 30
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
125000003545 alkoxy group Chemical group 0.000 claims description 27
125000003118 aryl group Chemical group 0.000 claims description 27
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 22
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 22
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 21
238000010438 heat treatment Methods 0.000 claims description 21
229910052760 oxygen Inorganic materials 0.000 claims description 21
229910052757 nitrogen Inorganic materials 0.000 claims description 19
125000000623 heterocyclic group Chemical group 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 15
125000001424 substituent group Chemical group 0.000 claims description 14
125000004442 acylamino group Chemical group 0.000 claims description 13
125000005842 heteroatom Chemical group 0.000 claims description 13
150000002431 hydrogen Chemical group 0.000 claims description 13
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
125000001544 thienyl group Chemical group 0.000 claims description 13
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
229910052717 sulfur Inorganic materials 0.000 claims description 12
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 11
238000001816 cooling Methods 0.000 claims description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 9
125000001624 naphthyl group Chemical group 0.000 claims description 9
XAPRFLSJBSXESP-UHFFFAOYSA-N oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 claims description 9
125000006413 ring segment Chemical group 0.000 claims description 9
229940086542 triethylamine Drugs 0.000 claims description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 8
125000003282 alkyl amino group Chemical group 0.000 claims description 8
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 8
125000005518 carboxamido group Chemical group 0.000 claims description 8
125000002541 furyl group Chemical group 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 7
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
AQFLVLHRZFLDDV-VIFPVBQESA-N (1s)-1-phenylpropan-1-amine Chemical compound CC[C@H](N)C1=CC=CC=C1 AQFLVLHRZFLDDV-VIFPVBQESA-N 0.000 claims description 6
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 6
125000000335 thiazolyl group Chemical group 0.000 claims description 6
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
125000002431 aminoalkoxy group Chemical group 0.000 claims description 5
125000003107 substituted aryl group Chemical group 0.000 claims description 4
PMZKDGRAZFDNFC-BVMKMSJKSA-N C=1C=CC=CC=1C(CC)NC(=O)C([C@@]1(O)C=2N=C3C=CC=CC3=CC=2)(C(O)=O)C2=CC=CC=C2NC1(C=1C=CC=CC=1)C1=CC=CC=C1 Chemical compound C=1C=CC=CC=1C(CC)NC(=O)C([C@@]1(O)C=2N=C3C=CC=CC3=CC=2)(C(O)=O)C2=CC=CC=C2NC1(C=1C=CC=CC=1)C1=CC=CC=C1 PMZKDGRAZFDNFC-BVMKMSJKSA-N 0.000 claims description 3
125000003884 phenylalkyl group Chemical group 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
FZFIIACJTIBJMH-UHFFFAOYSA-N ethyl 3-acetyloxy-2-phenylquinoline-4-carboxylate Chemical compound N=1C2=CC=CC=C2C(C(=O)OCC)=C(OC(C)=O)C=1C1=CC=CC=C1 FZFIIACJTIBJMH-UHFFFAOYSA-N 0.000 claims 1
239000000543 intermediate Substances 0.000 abstract description 21
230000008569 process Effects 0.000 abstract description 15
150000003248 quinolines Chemical class 0.000 abstract description 2
BIAVGWDGIJKWRM-FQEVSTJZSA-N 3-hydroxy-2-phenyl-n-[(1s)-1-phenylpropyl]quinoline-4-carboxamide Chemical compound N([C@@H](CC)C=1C=CC=CC=1)C(=O)C(C1=CC=CC=C1N=1)=C(O)C=1C1=CC=CC=C1 BIAVGWDGIJKWRM-FQEVSTJZSA-N 0.000 abstract 1
239000002585 base Substances 0.000 description 40
125000004356 hydroxy functional group Chemical group O* 0.000 description 31
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 15
239000000047 product Substances 0.000 description 15
229910001868 water Inorganic materials 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
150000001412 amines Chemical class 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
230000008878 coupling Effects 0.000 description 12
238000010168 coupling process Methods 0.000 description 12
238000005859 coupling reaction Methods 0.000 description 12
JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
229940061720 alpha hydroxy acid Drugs 0.000 description 8
150000001280 alpha hydroxy acids Chemical class 0.000 description 8
239000002253 acid Substances 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
102000002003 Neurokinin-3 Receptors Human genes 0.000 description 5
108010040716 Neurokinin-3 Receptors Proteins 0.000 description 5
239000006227 byproduct Substances 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000002464 receptor antagonist Substances 0.000 description 5
229940044551 receptor antagonist Drugs 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
125000004076 pyridyl group Chemical group 0.000 description 4
239000007787 solid Substances 0.000 description 4
150000003512 tertiary amines Chemical class 0.000 description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
125000004945 acylaminoalkyl group Chemical group 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 3
229910001863 barium hydroxide Inorganic materials 0.000 description 3
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
239000000920 calcium hydroxide Substances 0.000 description 3
235000011116 calcium hydroxide Nutrition 0.000 description 3
229910001861 calcium hydroxide Inorganic materials 0.000 description 3
229940095643 calcium hydroxide Drugs 0.000 description 3
150000007942 carboxylates Chemical class 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940125773 compound 10 Drugs 0.000 description 3
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000012065 filter cake Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
YRNDGUSDBCARGC-UHFFFAOYSA-N 2-methoxyacetophenone Chemical compound COCC(=O)C1=CC=CC=C1 YRNDGUSDBCARGC-UHFFFAOYSA-N 0.000 description 2
AOLMGSAMTRTYEX-UHFFFAOYSA-N 2-phenylquinoline-4-carboxamide Chemical compound N=1C2=CC=CC=C2C(C(=O)N)=CC=1C1=CC=CC=C1 AOLMGSAMTRTYEX-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
101150015280 Cel gene Proteins 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
206010046543 Urinary incontinence Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
239000000010 aprotic solvent Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000011210 chromatographic step Methods 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
BGAXCPSNMHVHJC-UHFFFAOYSA-N phenacyl acetate Chemical group CC(=O)OCC(=O)C1=CC=CC=C1 BGAXCPSNMHVHJC-UHFFFAOYSA-N 0.000 description 2
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
150000003254 radicals Chemical class 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
MXNVEJDRXSFZQB-UHFFFAOYSA-N 3-hydroxyquinoline-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=NC2=C1 MXNVEJDRXSFZQB-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
JVYMKTAPCLSXLC-UHFFFAOYSA-N COClO Chemical compound COClO JVYMKTAPCLSXLC-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010065390 Inflammatory pain Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
IMRFHKJOBUPLSP-UHFFFAOYSA-N [amino(hydroxy)-lambda3-chloranyl]oxymethane Chemical compound COCl(N)O IMRFHKJOBUPLSP-UHFFFAOYSA-N 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
230000036428 airway hyperreactivity Effects 0.000 description 1
150000001347 alkyl bromides Chemical class 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
229940125758 compound 15 Drugs 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
238000001035 drying Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
239000012071 phase Substances 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000000967 suction filtration Methods 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000013638 trimer Substances 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pulmonology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

OA1200000078A 1997-09-17 2000-03-16 Method for the synthesis of quinoline derivatives. OA11340A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US5930397P	1997-09-17	1997-09-17

Publications (1)

Publication Number	Publication Date
OA11340A true OA11340A (en)	2003-12-09

Family

ID=22022126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000078A OA11340A (en)	1997-09-17	2000-03-16	Method for the synthesis of quinoline derivatives.

Country Status (32)

Country	Link
US (6)	US6335448B1 (fr)
EP (1)	EP1017676B1 (fr)
JP (1)	JP2001516744A (fr)
KR (1)	KR20010024031A (fr)
CN (1)	CN1125815C (fr)
AP (1)	AP1201A (fr)
AR (1)	AR015445A1 (fr)
AT (1)	ATE353879T1 (fr)
AU (1)	AU744538B2 (fr)
BG (1)	BG104243A (fr)
BR (1)	BR9812085A (fr)
CA (1)	CA2303026A1 (fr)
DE (1)	DE69837100T2 (fr)
DZ (1)	DZ2607A1 (fr)
EA (1)	EA002633B1 (fr)
ES (1)	ES2283072T3 (fr)
HU (1)	HUP0004855A3 (fr)
ID (1)	ID24140A (fr)
IL (1)	IL134991A0 (fr)
MA (1)	MA24644A1 (fr)
MY (1)	MY120237A (fr)
NO (1)	NO314303B1 (fr)
NZ (1)	NZ503307A (fr)
OA (1)	OA11340A (fr)
PE (1)	PE129299A1 (fr)
PL (1)	PL339340A1 (fr)
SK (1)	SK3672000A3 (fr)
TR (1)	TR200000720T2 (fr)
TW (1)	TW509678B (fr)
UY (2)	UY25174A1 (fr)
WO (1)	WO1999014196A1 (fr)
ZA (1)	ZA988455B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP1201A (en) *	1997-09-17	2003-09-01	Smithkline Beecham Corp	Method for the synthesis of quinoline derivatives.
WO2000058313A1 (fr)	1999-03-29	2000-10-05	Neurogen Corporation	Derives de quinoline 4-substitues en tant que ligands des recepteurs de gaba
EA010369B1 (ru)	2004-02-04	2008-08-29	Пфайзер Продактс Инк.	Замещенные хинолиновые соединения
AU2006253054A1 (en) *	2005-06-03	2006-12-07	Astrazeneca Ab	Quinoline derivatives as NK3 anatgonists
WO2007016609A2 (fr) *	2005-08-02	2007-02-08	Smithkline Beecham Corporation	Procédé pour la synthèse de dérivés de la quinoline
EP1915363A1 (fr) *	2005-08-11	2008-04-30	AstraZeneca AB	Modulateurs récépteurs nk3 en tant qu'amides de quinoléine oxopyridyl
US20080234269A1 (en) *	2005-09-21	2008-09-25	Astrazeneca Ab	N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
AR057130A1 (es) *	2005-09-21	2007-11-14	Astrazeneca Ab	Quinolinas de alquilsulfoxido y una composicion farmaceutica
WO2007086799A1 (fr) *	2006-01-27	2007-08-02	Astrazeneca Ab	Quinoléines substituées par un amide
CN102924375B (zh) *	2012-06-21	2015-02-18	江苏恩华药业股份有限公司	Talnetant中间体及其制备方法和应用
CN102702099A (zh) *	2012-06-21	2012-10-03	江苏恩华药业股份有限公司	(s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
CN103214416A (zh) *	2013-04-26	2013-07-24	扬州大学	一种合成多取代喹啉类化合物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2776290A (en) *		1957-01-01		Hydroxy cevchoninates and carboxylic
RO114445B1 (ro) *	1994-05-27	1999-04-30	Smithkline Beecham S.P.A.	Derivaţi de chinolină antagonişti ai receptorului nk3 tachichinină,procedeu de preparare,compoziţii farmaceutice pe baza acestora şi metodă de tratament
US5627193A (en) *	1995-02-09	1997-05-06	Mitsui Toatsu Chemicals, Inc.	Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
AP1201A (en) *	1997-09-17	2003-09-01	Smithkline Beecham Corp	Method for the synthesis of quinoline derivatives.

1998
- 1998-05-08 AP APAP/P/2000/001767A patent/AP1201A/en active
- 1998-09-08 MA MA25246A patent/MA24644A1/fr unknown
- 1998-09-08 UY UY25174A patent/UY25174A1/es not_active Application Discontinuation
- 1998-09-11 PE PE1998000868A patent/PE129299A1/es not_active Application Discontinuation
- 1998-09-14 DZ DZ980217A patent/DZ2607A1/fr active
- 1998-09-15 MY MYPI98004207A patent/MY120237A/en unknown
- 1998-09-16 AR ARP980104603A patent/AR015445A1/es not_active Application Discontinuation
- 1998-09-16 ZA ZA988455A patent/ZA988455B/xx unknown
- 1998-09-17 EP EP98947099A patent/EP1017676B1/fr not_active Expired - Lifetime
- 1998-09-17 NZ NZ503307A patent/NZ503307A/en unknown
- 1998-09-17 IL IL13499198A patent/IL134991A0/xx unknown
- 1998-09-17 HU HU0004855A patent/HUP0004855A3/hu unknown
- 1998-09-17 BR BR9812085-9A patent/BR9812085A/pt not_active IP Right Cessation
- 1998-09-17 US US09/508,358 patent/US6335448B1/en not_active Expired - Fee Related
- 1998-09-17 WO PCT/US1998/019434 patent/WO1999014196A1/fr not_active Ceased
- 1998-09-17 EA EA200000322A patent/EA002633B1/ru not_active IP Right Cessation
- 1998-09-17 SK SK367-2000A patent/SK3672000A3/sk unknown
- 1998-09-17 TR TR2000/00720T patent/TR200000720T2/xx unknown
- 1998-09-17 PL PL98339340A patent/PL339340A1/xx unknown
- 1998-09-17 ID IDW20000498A patent/ID24140A/id unknown
- 1998-09-17 DE DE69837100T patent/DE69837100T2/de not_active Expired - Lifetime
- 1998-09-17 CN CN98810978A patent/CN1125815C/zh not_active Expired - Fee Related
- 1998-09-17 CA CA002303026A patent/CA2303026A1/fr not_active Abandoned
- 1998-09-17 JP JP2000511747A patent/JP2001516744A/ja active Pending
- 1998-09-17 AT AT98947099T patent/ATE353879T1/de not_active IP Right Cessation
- 1998-09-17 AU AU93958/98A patent/AU744538B2/en not_active Ceased
- 1998-09-17 KR KR1020007002766A patent/KR20010024031A/ko not_active Ceased
- 1998-09-17 ES ES98947099T patent/ES2283072T3/es not_active Expired - Lifetime
- 1998-09-29 TW TW087114858A patent/TW509678B/zh not_active IP Right Cessation
1999
- 1999-02-26 UY UY25407A patent/UY25407A1/es unknown
2000
- 2000-03-15 BG BG104243A patent/BG104243A/xx unknown
- 2000-03-16 OA OA1200000078A patent/OA11340A/en unknown
- 2000-03-16 NO NO20001387A patent/NO314303B1/no not_active IP Right Cessation
2001
- 2001-10-17 US US09/981,185 patent/US20020038029A1/en not_active Abandoned
2002
- 2002-06-17 US US10/174,458 patent/US20020173657A1/en not_active Abandoned
2003
- 2003-05-20 US US10/441,708 patent/US20040049031A1/en not_active Abandoned
2005
- 2005-03-30 US US11/093,701 patent/US20050171152A1/en not_active Abandoned
2006
- 2006-04-28 US US11/413,932 patent/US20060189809A1/en not_active Abandoned

Also Published As

Publication number	Publication date
UY25174A1 (es)	2001-07-31
US20040049031A1 (en)	2004-03-11
MY120237A (en)	2005-09-30
US20060189809A1 (en)	2006-08-24
IL134991A0 (en)	2001-05-20
TW509678B (en)	2002-11-11
ID24140A (id)	2000-07-06
WO1999014196A1 (fr)	1999-03-25
US6335448B1 (en)	2002-01-01
EA200000322A1 (ru)	2000-10-30
DE69837100T2 (de)	2007-11-22
AP2000001767A0 (en)	2000-03-31
US20020038029A1 (en)	2002-03-28
HUP0004855A2 (hu)	2001-06-28
HUP0004855A3 (en)	2001-08-28
MA24644A1 (fr)	1999-04-01
AR015445A1 (es)	2001-05-02
ATE353879T1 (de)	2007-03-15
AU9395898A (en)	1999-04-05
ZA988455B (en)	1999-02-17
NO20001387D0 (no)	2000-03-16
CN1125815C (zh)	2003-10-29
ES2283072T3 (es)	2007-10-16
DE69837100D1 (de)	2007-03-29
PL339340A1 (en)	2000-12-18
AU744538B2 (en)	2002-02-28
NZ503307A (en)	2002-04-26
EP1017676B1 (fr)	2007-02-14
EP1017676A4 (fr)	2002-12-04
NO20001387L (no)	2000-03-16
BR9812085A (pt)	2000-09-26
SK3672000A3 (en)	2000-09-12
CA2303026A1 (fr)	1999-03-25
EP1017676A1 (fr)	2000-07-12
BG104243A (en)	2001-05-31
TR200000720T2 (tr)	2000-08-21
NO314303B1 (no)	2003-03-03
JP2001516744A (ja)	2001-10-02
UY25407A1 (es)	1999-11-17
US20020173657A1 (en)	2002-11-21
KR20010024031A (ko)	2001-03-26
US20050171152A1 (en)	2005-08-04
DZ2607A1 (fr)	2003-03-01
PE129299A1 (es)	2000-02-19
EA002633B1 (ru)	2002-08-29
AP1201A (en)	2003-09-01
CN1278796A (zh)	2001-01-03

Publication	Publication Date	Title
US5401753A (en)	1995-03-28	Substituted n-heteroaryl-1, 2-diaminocyclobutene-3, 3-diones
JP4386723B2 (ja)	2009-12-16	新規方法
IE862605L (en)	1987-04-28	Preparation of disubstituted pyridine -2,3- dicarboxylates
EP1017676B1 (fr)	2007-02-14	Procede de synthese de derives de quinoleine
JP2004518737A (ja)	2004-06-24	２−（４−クロロベンゾイルアミノ）−３−［２（１ｈ）−キノールリノン−４−イル］プロピオン酸の製造方法
JP3850838B2 (ja)	2006-11-29	トランス−４−アミノ−１−シクロヘキサンカルボン酸誘導体の製造方法
CN1330627C (zh)	2007-08-08	N－酰基－2－氨基－4－烷氧基－5－硝基苯甲酸类化合物的合成方法
SK280074B6 (sk)	1999-07-12	Spôsob prípravy flunixínu a medziprodukt tohto spô
CN1093128C (zh)	2002-10-23	制备依普沙坦的方法
CN88100318A (zh)	1988-08-03	喹诺酮羧酸的制备及其中间体
JPH08507496A (ja)	1996-08-13	ジアミノピリジンの製法
EP1652840A2 (fr)	2006-05-03	(-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
MXPA00002695A (en)	2002-03-26	Method for the synthesis of quinoline derivatives
JPH0841029A (ja)	1996-02-13	３−置換キノリン−５−カルボン酸誘導体およびその製造法
AU1020902A (en)	2002-03-14	Method for the synthesis of quinoline derivatives
DE69700122T2 (de)	1999-08-12	Verfahren zur Herstellung von Dithiocarbonimidderivate
JP2001097933A (ja)	2001-04-10	光学活性２−アミノシクロヘキサノール誘導体の製造法
CZ2000922A3 (cs)	2000-09-13	Způsob syntézy chinolinových derivátů
JP2004506634A (ja)	2004-03-04	イミダゾピリジン類の製造方法
JPH0525162A (ja)	1993-02-02	キノロン誘導体およびその製造法
CA1326239C (fr)	1994-01-18	Preparation de la ciprofloxacine
US4659826A (en)	1987-04-21	Synthesis of salicylamides with improved yield and purity
JPH03130252A (ja)	1991-06-04	２―アミノ―５―メチルベンゾフェノン類及びその製造法
JP2001502715A (ja)	2001-02-27	ナフチリジン化合物および新規中間体の製造体
JP2005289896A (ja)	2005-10-20	２−オキシインドール誘導体の製造法